TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28213480

Group type: EXPERIMENTAL
Intervention: Dofetilide
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Quinidine
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 28213596

Group type: EXPERIMENTAL
Intervention: Total white cell count (WBC) within the normal range (8.65-10.05×10^9/L)
Number of subjects: 880988

Group type: EXPERIMENTAL
Intervention: High WBC within the reference range
Number of subjects: 880988
Study: 28213664

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 20
Study: 28213684

Group type: EXPERIMENTAL
Intervention: Community-based chronic care overweight and obesity treatment
Number of subjects: 477
Study: 28213781

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy (SLNB) before NAST
Number of subjects: 224
Study: 28213914

Group type: EXPERIMENTAL
Intervention: Chronic autonomic regulation therapy (ART) with vagus nerve stimulation (VNS) at 10 Hz, 250 μs pulse width, 18% duty cycle, maximum tolerable current amplitude after 10 weeks of titration
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Chronic autonomic regulation therapy (ART) with vagus nerve stimulation (VNS)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Patients with symptomatic heart failure
Number of subjects: 21
Study: 28213943

Group type: EXPERIMENTAL
Intervention: Elotuzumab (10 mg/kg, accelerated infusion over ∼1 h), combined with lenalidomide (25 mg daily, Days 1-21) and dexamethasone (28 mg orally and 8 mg intravenously, weekly, Cycles 1-2; 40 mg orally, weekly, Cycles 3+)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Elotuzumab (10 mg/kg, standard infusion over ∼3 h), combined with lenalidomide and dexamethasone (from previous phase 3 study)
Number of subjects: 70
Study: 28214655

Group type: EXPERIMENTAL
Intervention: Eribulin treatment
Number of subjects: 65
Study: 28214792

Group type: EXPERIMENTAL
Intervention: sST2 levels measured in HFpEF patients
Number of subjects: 174
Study: 28214794

Group type: EXPERIMENTAL
Intervention: Intensive lipid-lowering therapy (LLT) for those with ≥3% 5-year absolute major cardiovascular events risk reduction (ARR)
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Intensive LLT for those with ≥2.3% ARR
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Intensive LLT for those with ≥1.5% ARR
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Intensive LLT for all coronary artery disease patients
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Benefit-based treatment
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Standard LLT for all (reference strategy)
Number of subjects: 10000
Study: 28215251

Group type: EXPERIMENTAL
Intervention: Caffeine consumption in T allele carriers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Caffeine consumption in CC genotype
Number of subjects: 0
Study: 28215851

Group type: EXPERIMENTAL
Intervention: Neoadjuvant Stereotactic Body Radiotherapy (SBRT) at escalating doses (35, 40, 45, and 50 Gy) in 10 daily fractions
Number of subjects: 20
Study: 28215937

Group type: EXPERIMENTAL
Intervention: Evolocumab 420 mg subcutaneously monthly (or every 2 weeks if on apheresis)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Evolocumab (increased dosing to every 2 weeks)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Evolocumab (in patients on apheresis)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 106
Study: 28216350

Group type: EXPERIMENTAL
Intervention: Color-coded quantitative digital subtraction angiography (CQDSA)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: TTP ≤5 seconds
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Mixed-type endoleak
Number of subjects: 35
Study: 28216359

Group type: EXPERIMENTAL
Intervention: Fenestrated endovascular aneurysm repair (FEVAR)
Number of subjects: 85
Study: 28218593

Group type: EXPERIMENTAL
Intervention: In-car video feedback intervention (3 months of intervention with weekly reports, DVD of unsafe events, and telephone contacts)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Postintervention monitoring (3 months)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: In-car video feedback intervention
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Postintervention monitoring
Number of subjects: 12
Study: 28218598

Group type: EXPERIMENTAL
Intervention: VISION COACH™ interactive light board
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional Object Detection
Number of subjects: 0
Study: 28219323

Group type: EXPERIMENTAL
Intervention: LMA Protector™
Number of subjects: 26
Study: 28219331

Group type: EXPERIMENTAL
Intervention: Imago V-Blade®
Number of subjects: 42

Group type: COMPARATOR
Intervention: Glidescope®
Number of subjects: 42
Study: 28219399

Group type: EXPERIMENTAL
Intervention: Non-invasive cochlear microphonic (CM) phase monitoring
Number of subjects: 24

Group type: COMPARATOR
Intervention: Invasive ICP monitoring
Number of subjects: 24
Study: 28219443

Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (ERT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Total splenectomy
Number of subjects: 0
Study: 28219694

Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg per day for 21 of 28 days until lymphoma progression or unacceptable toxicity
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 48
Study: 28219916

Group type: EXPERIMENTAL
Intervention: Carotid-femoral pulse-wave velocity (cf-PWV)
Number of subjects: 1599

Group type: EXPERIMENTAL
Intervention: Brachial-ankle pulse-wave velocity (ba-PWV)
Number of subjects: 1599

Group type: EXPERIMENTAL
Intervention: Both cf-PWV and ba-PWV
Number of subjects: 1599
Study: 28219925

Group type: EXPERIMENTAL
Intervention: Consistent long-term heavy alcohol intake >112 g of ethanol/week
Number of subjects: 3869

Group type: EXPERIMENTAL
Intervention: Longitudinal variability in alcohol consumption
Number of subjects: 3869
Study: 28220197

Group type: EXPERIMENTAL
Intervention: EWGSOP definition
Number of subjects: 965

Group type: EXPERIMENTAL
Intervention: IWGS definition
Number of subjects: 965

Group type: EXPERIMENTAL
Intervention: FNIH definition
Number of subjects: 965

Group type: EXPERIMENTAL
Intervention: EWGSOP + body fat >25%
Number of subjects: 965

Group type: EXPERIMENTAL
Intervention: IWGS + body fat >30%
Number of subjects: 965
Study: 28220753

Group type: EXPERIMENTAL
Intervention: Intracortical brain-computer interface (iBCI) for communication
Number of subjects: 3
Study: 28221201

Group type: EXPERIMENTAL
Intervention: Pronto-7™ (Masimo Corporation)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: NBM-200MP™ (OrSense Ltd)
Number of subjects: 44
Study: 28221206

Group type: EXPERIMENTAL
Intervention: New pathological Q waves (anterior) in V1 to V5
Number of subjects: 1464

Group type: EXPERIMENTAL
Intervention: New pathological Q waves (any location)
Number of subjects: 1464

Group type: EXPERIMENTAL
Intervention: Overall cohort (n=1464)
Number of subjects: 1464

Group type: EXPERIMENTAL
Intervention: Definite or probable new pathological Q waves
Number of subjects: 1464
Study: 28221298

Group type: EXPERIMENTAL
Intervention: MR-proADM
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: PCT
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: MR-proADM and PCT
Number of subjects: 42
Study: 28221823

Group type: EXPERIMENTAL
Intervention: MiniMed 640G 'suspend before low' feature set at 65 mg/dL, predicting hypoglycemia and suspending insulin delivery when glucose was predicted to be ≤85 mg/dL.
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: MiniMed 640G 'suspend before low' feature
Number of subjects: 69
Study: 28221867

Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg once daily
Number of subjects: 201
Study: 28222073

Group type: EXPERIMENTAL
Intervention: Oral rucaparib (240 mg per day) combined with carboplatin (AUC 5 mg/ml)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Intravenous rucaparib combined with various chemotherapy regimens (carboplatin, carboplatin/paclitaxel, cisplatin/pemetrexed, epirubicin/cyclophosphamide)
Number of subjects: 85
Study: 28222139

Group type: EXPERIMENTAL
Intervention: Anti-PGL-I serology
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Anti-LID-1 serology
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Anti-ND-O-LID serology
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Bacilloscopic index (BI) categories
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: BI categories (0<BI<3)
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: BI≥3
Number of subjects: 452
Study: 28222249

Group type: EXPERIMENTAL
Intervention: Aspartate aminotransferase to platelet ratio index
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: FIB-4
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: Gamma-glutamyl transpeptidase to platelet ratio
Number of subjects: 582
Study: 28222707

Group type: EXPERIMENTAL
Intervention: STarT Back Screening Tool (SBT)
Number of subjects: 329

Group type: COMPARATOR
Intervention: Örebro Musculoskeletal Pain Screening Questionnaire (ÖMPSQ-short)
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: SBT and ÖMPSQ-short classification to high or low risk for long-term pain and disability
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: SBT in clinical practice
Number of subjects: 329
Study: 28223036

Group type: EXPERIMENTAL
Intervention: Moderate exercise
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Vigorous exercise
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study: 28223062

Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg every 2 weeks)
Number of subjects: 37
Study: 28223297

Group type: EXPERIMENTAL
Intervention: Metreleptin therapy
Number of subjects: 8
Study: 28223428

Group type: EXPERIMENTAL
Intervention: Pipeline Flex Embolization Device with Shield Technology (PFLEX)
Number of subjects: 50
Study: 28223466

Group type: EXPERIMENTAL
Intervention: Autogenic drainage
Number of subjects: 24
Study: 28224463

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 0
Study: 28225505

Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg/d
Number of subjects: 1

Group type: COMPARATOR
Intervention: Conventional optimal medical therapy
Number of subjects: 1
Study: 28225683

Group type: EXPERIMENTAL
Intervention: Screening for Chlamydia trachomatis infections
Number of subjects: 0
Study: 28226027

Group type: EXPERIMENTAL
Intervention: Highest vitamin D levels
Number of subjects: 63

Group type: COMPARATOR
Intervention: Lowest vitamin D levels
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Vitamin D levels
Number of subjects: 63
Study: 28226404

Group type: EXPERIMENTAL
Intervention: Proportion cortex estimated using NPHS2 expression
Number of subjects: 1190

Group type: EXPERIMENTAL
Intervention: Molecular scores for antibody-mediated rejection, T cell-mediated rejection, and injury
Number of subjects: 1190

Group type: EXPERIMENTAL
Intervention: Agreement in molecular diagnoses in paired cortex/medulla samples
Number of subjects: 1190
Study: 28228115

Group type: EXPERIMENTAL
Intervention: Intensive diet-induced weight loss of 10% combined with exercise
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: Intensive diet-induced weight loss and exercise intervention
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: Community program for diet-induced weight loss and exercise
Number of subjects: 820
Study: 28228116

Group type: EXPERIMENTAL
Intervention: Intervention year 1 cohort
Number of subjects: 1233

Group type: EXPERIMENTAL
Intervention: Intervention year 2 cohort
Number of subjects: 1233

Group type: EXPERIMENTAL
Intervention: Intervention year 1 and year 2 cohorts
Number of subjects: 1233
Study: 28228123

Group type: EXPERIMENTAL
Intervention: Supervised exercise group (EG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 0
Study: 28228318

Group type: EXPERIMENTAL
Intervention: Cord blood of offspring from mothers with PCOS
Number of subjects: 143

Group type: COMPARATOR
Intervention: Cord blood of healthy controls
Number of subjects: 143
Study: 28228332

Group type: EXPERIMENTAL
Intervention: Low fat diet
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Low glycemic load diet
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Maintenance Phase (no food provision and no in-person contact)
Number of subjects: 27
Study: 28228369

Group type: EXPERIMENTAL
Intervention: Postoperative wound monitoring using smartphone digital images
Number of subjects: 40
Study: 28228422

Group type: EXPERIMENTAL
Intervention: Receipt of palatable food
Number of subjects: 0
Study: 28228453

Group type: EXPERIMENTAL
Intervention: NOCAD patients
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Women with NOCAD
Number of subjects: 523

Group type: COMPARATOR
Intervention: Men and women with NOCAD
Number of subjects: 523

Group type: COMPARATOR
Intervention: General population (reference group)
Number of subjects: 523
Study: 28228461

Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein (hsCRP) measured 1 month after AMI
Number of subjects: 2219

Group type: EXPERIMENTAL
Intervention: Lipoprotein-associated phospholipase A2 measured 1 month after AMI
Number of subjects: 2219

Group type: EXPERIMENTAL
Intervention: hsCRP levels and health status at 12 months
Number of subjects: 2219

Group type: EXPERIMENTAL
Intervention: Residual inflammatory risk (hsCRP >3 mg/L)
Number of subjects: 2219
Study: 28228508

Group type: EXPERIMENTAL
Intervention: Breast milk iodine concentration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Urinary iodine concentration
Number of subjects: 0
Study: 28228848

Group type: EXPERIMENTAL
Intervention: Common Brazilian meal pattern (white rice, beans, beer, processed and fresh meats)
Number of subjects: 10010

Group type: EXPERIMENTAL
Intervention: Common Brazilian fast foods/full fat dairy/milk based desserts pattern
Number of subjects: 10010

Group type: EXPERIMENTAL
Intervention: DASH Diet pattern
Number of subjects: 10010

Group type: EXPERIMENTAL
Intervention: Diet, light foods and beverages/low fat dairy pattern
Number of subjects: 10010

Group type: EXPERIMENTAL
Intervention: Vegetables/fruit dietary pattern
Number of subjects: 10010
Study: 28228938

Group type: EXPERIMENTAL
Intervention: 6-week in-hospital exercise training programme
Number of subjects: 39

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 39
Study: 28229126

Group type: EXPERIMENTAL
Intervention: Intravenous solanezumab
Number of subjects: 1322

Group type: COMPARATOR
Intervention: Caregiver assessment
Number of subjects: 1322

Group type: COMPARATOR
Intervention: Clinical/health measures
Number of subjects: 1322
Study: 28229893

Group type: EXPERIMENTAL
Intervention: Natalizumab 300 mg intravenous
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study: 28230575

Group type: EXPERIMENTAL
Intervention: Qualitative study with semistructured interviews
Number of subjects: 22
Study: 28230704

Group type: EXPERIMENTAL
Intervention: Obstructive Sleep Apnea (OSA) group
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both groups during handgrip exercise
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both groups during PHMI
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Changes in MSNA due to PHMI
Number of subjects: 31
Study: 28231027

Group type: EXPERIMENTAL
Intervention: Insomnia symptoms
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Poor sleep quality
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Daytime sleepiness
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Depression symptoms
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Anxiety symptoms
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Sleep quality
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Insomnia and poor sleep quality
Number of subjects: 66
Study: 28231247

Group type: EXPERIMENTAL
Intervention: Favipiravir
Number of subjects: 66
Study: 28231622

Group type: EXPERIMENTAL
Intervention: Localized aggressive periodontitis (LAgP)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Generalized aggressive periodontitis (GAgP)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Healthy controls (H)
Number of subjects: 160
Study: 28231791

Group type: EXPERIMENTAL
Intervention: Peer-delivered Thinking Healthy Programme for perinatal depression, delivered over six months by trained peers.
Number of subjects: 44
Study: 28231807

Group type: EXPERIMENTAL
Intervention: Direct measures of adiposity (DXA-derived)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Indirect measures of adiposity
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Combination of direct and indirect measures of adiposity
Number of subjects: 288
Study: 28231814

Group type: EXPERIMENTAL
Intervention: HEMS
Number of subjects: 1068

Group type: COMPARATOR
Intervention: GEMS
Number of subjects: 1068
Study: 28231834

Group type: EXPERIMENTAL
Intervention: IL-5-, IL-17A-/F- and IL-25- high profile (Cluster 1, n=24)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: IL-5-high or IL-10-high (Cluster 2, n=16)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: IL-6-high (Cluster 3, n=8)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: IL-22-high (Cluster 4, n=25)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: No cytokine-high pattern or only high IL-4 and/or IL-13 (Cluster 5, n=132)
Number of subjects: 205
Study: 28231838

Group type: EXPERIMENTAL
Intervention: Continuous measurement of maximum diameter using cardiovascular magnetic resonance (CMR) scans
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Continuous measurement of maximum diameter using CMR
Number of subjects: 15
Study: 28231942

Group type: EXPERIMENTAL
Intervention: Ezetimibe and simvastatin
Number of subjects: 17717

Group type: COMPARATOR
Intervention: Placebo and simvastatin
Number of subjects: 17717
Study: 28233565

Group type: EXPERIMENTAL
Intervention: Intravenous hydration
Number of subjects: 660

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 660
Study: 28233591

Group type: EXPERIMENTAL
Intervention: Vessel-sparing radiotherapy
Number of subjects: 135
Study: 28235011

Group type: EXPERIMENTAL
Intervention: Industry-originated trials (N = 9 trials)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Patients who had not completed high school
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Overall patient understanding
Number of subjects: 50

Group type: COMPARATOR
Intervention: Type of cancer therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Trial sponsor
Number of subjects: 50
Study: 28235771

Group type: EXPERIMENTAL
Intervention: Immunotherapy with histamine dihydrochloride (HDC) and low-dose IL-2
Number of subjects: 84
Study: 28235835

Group type: EXPERIMENTAL
Intervention: Most educated mothers (22% exclusively breastfed)
Number of subjects: 1598

Group type: COMPARATOR
Intervention: Least educated mothers (7% exclusively breastfed)
Number of subjects: 1598

Group type: EXPERIMENTAL
Intervention: Adjusted for sociodemographic factors, smoking habits, and breastfeeding difficulties
Number of subjects: 1598
Study: 28235848

Group type: EXPERIMENTAL
Intervention: LQT2 patients underwent a 6-hour 75-g oral glucose tolerance test with ECG recording and blood sampling.
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control participants underwent the same 6-hour 75-g oral glucose tolerance test.
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: LQT2 patients during glucose ingestion.
Number of subjects: 33
Study: 28235964

Group type: EXPERIMENTAL
Intervention: 40 minutes of moderate physical activity per school day (intervention group)
Number of subjects: 1339

Group type: COMPARATOR
Intervention: 60 minutes of physical activity per week (control group)
Number of subjects: 1339
Study: 28236024

Group type: EXPERIMENTAL
Intervention: PulmoBind SPECT imaging
Number of subjects: 30
Study: 28236727

Group type: EXPERIMENTAL
Intervention: Brivaracetam 50mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brivaracetam 100mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brivaracetam 200mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28237286

Group type: EXPERIMENTAL
Intervention: HAS-BLED score (refined form excluding 'labile INR')
Number of subjects: 4579

Group type: EXPERIMENTAL
Intervention: HAS-BED score
Number of subjects: 4579

Group type: COMPARATOR
Intervention: CHADS score
Number of subjects: 4579
Study: 28237791

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 4032

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 4032

Group type: EXPERIMENTAL
Intervention: Bariatric surgery (in prediabetes subgroup)
Number of subjects: 4032

Group type: EXPERIMENTAL
Intervention: Bariatric surgery (in screen-detected diabetes subgroup)
Number of subjects: 4032

Group type: EXPERIMENTAL
Intervention: Bariatric surgery (in established diabetes subgroup)
Number of subjects: 4032

Group type: EXPERIMENTAL
Intervention: Bariatric surgery (in normoglycaemia subgroup)
Number of subjects: 4032
Study: 28238111

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 6
Study: 28238467

Group type: EXPERIMENTAL
Intervention: Micronutrient intake assessment
Number of subjects: 904
Study: 28238482

Group type: EXPERIMENTAL
Intervention: BMI-SDS reduction in girls
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: BMI-SDS reduction in boys
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: BMI-SDS reduction
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: LH concentration and LH/FSH ratio
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Homeostatic model assessment, IGF-1, and IGF-1/IGFBP-3 ratio
Number of subjects: 160
Study: 28238483

Group type: EXPERIMENTAL
Intervention: Psychological factors
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Disease activity
Number of subjects: 127
Study: 28238563

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CA4P plus bevacizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: CA4P plus pazopanib
Number of subjects: 0

Group type: COMPARATOR
Intervention: CA4P plus bevacizumab and chemotherapy
Number of subjects: 0